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EDITORIAL
The Smooth Muscle Cell: Sinner or Saint in Restenosis and the Acute
Coronary Syndromes?
ANTOINE LAFONT, MD, PETER LIBBY, MD, FACC*
Paris, France, and Boston, Massachusetts
Proliferation of arterial smooth muscle cells has held center
stage as the culprit in restenosis for almost two decades. Many
strategies for combating restenosis target smooth muscle replica-
tion. However, none have proven beneficial in clinical trials.
Indeed, inhibition of smooth muscle proliferation in human
patients might produce the undesired effect of destabilizing
vulnerable atherosclerotic plaques because these cells furnish the
collagen responsible for the biomechanical strength of the plaque.
Actually, in some cases the benefit of angioplasty may depend on
stimulating smooth muscle replication and collagen elaboration,
converting an “unstable” to a more stable plaque. Moreover,
recent clinical and experimental evidence suggests that restenosis
depends less on neointimal hyperplasia than on constrictive
remodeling (i.e., advential scarring, producing a smaller lumen),
a process independent of smooth muscle replication. The recog-
nition that plaques vulnerable to disruption often do not produce
flow-limiting stenoses highlights a need for reassessment of the
strategies to treat or prevent the acute coronary syndromes. We
should strive to treat aggressively risk factors such as hyperlip-
idemia whose control appears to stabilize plaques. Trials are even
underway comparing such risk factor management with coronary
artery intervention. If we could identify potentially unstable
atheroma before they are evident, clinically, we might even
contemplate angioplasty of nonsignificant stenoses to induce
smooth muscle cell proliferation and reinforce the plaque’s fi-
brous cap. This proposal may seem preposterous, yet we perform
“primary” angioplasty every day in patients with an acute myo-
cardial infarction whose “culprit” lesions underlying the throm-
bus are often not critical. Our knowledge of the biology of
restenosis has lagged behind our practice of coronary interven-
tion. Advances in understanding the biology of the complications
of interventional therapy, hand in hand with technical advances,
should help us to devise more rational and enduring approaches
to benefiting our patients.
(J Am Coll Cardiol 1998;32:283–5)
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Since the introduction of percutaneous balloon angioplasty as
a treatment of human coronary artery stenosis some two
decades ago, proliferation of arterial smooth muscle cells has
held center stage as the protagonist in restenosis, a complica-
tion that has dogged the long-term success of this modality in
many patients (1,2). A number of gene transfer–related strat-
egies currently aimed at combating restenosis after angioplasty
target smooth muscle replication. However, we speculated in
1995 that “Inhibition of smooth muscle proliferation in human
patients might produce the undesired effect of destabilizing
vulnerable regions of atherosclerotic plaques . . .” (3). Smooth
muscle cell proliferation was subsequently proposed as a
therapy for plaque stabilization (4). Indeed, in certain cases the
major mechanism of benefit of angioplasty may depend on
smooth muscle replication and elaboration of a collagenous
extracellular matrix. Overstretching a stenosed artery wall to
render the inner lumen equal to the upstream normal lumen
with a balloon induces an injury that not only macroscopically
destroys the artery’s structure, but can modulate smooth
muscle cell function from quiescence to a proliferative, migra-
tory and extracellular matrix-producing phenotype (5,6). In
this respect, angioplasty constitutes a kind of gene therapy
itself, not requiring transfer of exogenous genetic material, but
eliciting a new program of endogenous gene expression. Func-
tions of smooth muscle cells so altered by angioplasty can
dramatically alter the structure of the dilated artery for several
months.
Curiously, we have used coronary angioplasty for two
decades without understanding how it works. Initially, Gruent-
zig et al. (7) intended to remodel the artery wall by compress-
ing the plaque underlying the stenosis without deep arterial
injury. Pathologic studies (8) later demonstrated that balloon
angioplasty actually fractures plaques and distends the artery
wall, often expanding the portion with less plaque in eccentric
lesions. In response to this injury, smooth muscle cell prolif-
eration, migration and matrix synthesis may contribute to the
formation of a thickened intima in experimental animal mod-
els. Thus, in humans, neointimal hyperplasia was presumed
responsible for restenosis, which plagued up to 30% to 50% of
angioplastied vessels (9). We and others (10–15) have recently
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shown that restenosis does not necessarily depend on neointi-
mal hyperplasia after experimental angioplasty, a concept now
verified in patients by intravascular ultrasound observations
revealing that intima–media thicknesses are similar in arteries
with or without angiographically determined restenosis after
angioplasty.
Moreover, stenting, which is known to induce smooth
muscle proliferation, represents the first interventional strat-
egy able to maintain lumen caliber sufficiently to lessen the
need for further therapy (although this results primarily from
the more effective initial dilation achieved) (16–18). In most
cases of restenosis, constrictive remodeling, including adventi-
tial scarring producing a smaller lumen, appears to be the
principal mechanism of restenosis, exonerating intimal smooth
muscle cell proliferation and calling into question strategies
that target this process (19–21).
Rather than focus on the decrease in lumen caliber known
as restenosis that occurs in a minority of patients after angio-
plasty, it is instructive to consider why the majority of plaques
become clinically stable after this iatrogenic injury. Thrombo-
sis (usually on disrupted plaque) causes most acute coronary
syndromes. Indeed, atherectomy samples showed a clear rela-
tion between prevalence of thrombus and the clinical scoring
system of the Braunwald classification (22). After angioplasty,
the wounding by the balloon induces a healing response
prominently featuring extracellular matrix elaboration by
smooth muscle cells (23). This matrix can reinforce the fibrous
skeleton of previously fragile atheromata, as shown by intra-
vascular ultrasound (14). Angioscopy has revealed that healing
after angioplasty results in a smooth, concentric, white plaque
surface lacking the thrombi present in .70% of culprit lesions
producing unstable angina (24). These observations demon-
strate directly the healing process evoked by angioplasty.
Human atherosclerotic plaques prone to rupture appear to
have friable fibrous caps weakened by relative lack of extracel-
lular matrix. This impaired matrix skeleton may result from
reduced synthesis of the macromolecules of the extracellular
matrix or excessive activity of enzymes, such as matrix metal-
loproteinases, which digest the extracellular matrix (3). Indeed,
sites where human coronary plaques rupture and produce
thrombosis characteristically have few smooth muscle cells,
and we have fostered the notion that such regions of athero-
sclerotic plaque may undergo attrition of smooth muscle cells
by death, including apoptotic mechanisms, as a consequence of
local inflammation (25). Thus, the lack of smooth muscle cells,
rather than their excess, seems to correlate with the dreaded
thrombotic complications of coronary artery disease, such as
unstable angina and acute myocardial infarction.
The recognition that plaques vulnerable to disruption most
often do not produce flow-limiting stenoses should occasion a
reassessment of the strategies to treat or prevent the acute
coronary syndromes (26). Should we, for example, perform
angioplasty of nonsignificant stenoses to induce smooth muscle
cell proliferation? This proposal seems preposterous, yet car-
diologists perform “primary” angioplasty every day in patients
in the throes of acute myocardial infarction, in whom we have
learned that the “culprit” lesion underlying the occluding
thrombus produces a fixed stenosis .70% in ,15% of cases
(27–29).
Of course, preventing plaque rupture by performing angio-
plasty in nonocclusive atheroma would require methods to
identify a priori patients at risk and lesions prone to rupture.
Cardiologists must now adopt the stance of geologists who
attempt to predict which dormant volcano will erupt when, or
which seismic fault will give way at what moment to produce a
calamitous event. Perhaps plasma markers of inflammation
(e.g., C-reactive protein, soluble adhesion molecules) will help
us to identify the patients at risk. Noninvasive imaging modal-
ities, such as magnetic resonance, may help pinpoint plaques
susceptible to rupture in such patients. Such subsets of patients
would be selected for intensive medical intervention aimed at
stabilizing plaques, some proven (e.g., lipid lowering), others
more speculative (e.g., anti-inflammatory agents, metallopro-
teinase inhibitors). In some cases, even “prophylactic” angio-
plasty may prove beneficial.
From the “classical” view of smooth muscle cell prolifera-
tion as the enemy after angioplasty, we have begun to accept
the concept that intimal cell replication may not play a decisive
role in the pathogenesis of restenosis. We should now consider
that smooth muscle cell proliferation in some situations may
even prove beneficial, furnishing a necessary part of both the
healing process after clinical or iatrogenic plaque rupture
(angioplasty). This heretical view will doubtless require time to
become accepted, even though it is already being implemented
in the clinic. This would not the first time that understanding of
a biological mechanism followed empiric adoption of a treat-
ment by practitioners.
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